ArticleJournal of dental sciences2026
Ovatodiolide overcomes cisplatin resistance in head and neck cancer by disrupting a novel oncogenic signature and cancer-associated fibroblast activation.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Malignant head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with complex tumor microenvironment interactions. We aimed to identify key molecular drivers and therapeutic targets using bioinformatics approaches and examine their associations with cancer-associated fibroblasts (CAF). Materials and methods: We analyzed three HNSCC transcriptomic datasets using bioinformatics. Protein-protein interaction networks were created using STRING, and pathway enrichment was also performed. The clinical relevance and CAF association of genes were evaluated using the TCGA HNSCC cohort and TIMER 2.0. Molecular docking predicted ovatodiolide binding to target proteins. Bioinformatics findings were validated in HNSCC cell lines and normal fibroblasts (WS1) by assessing cell viability, tumor spheroid formation, and CAF transformation through viability assays, qPCR, and Western blot. A mouse model of cisplatin resistance was used to test ovatodiolide's therapeutic effect. Results: Our bioinformatics identified a nine-gene oncogenic network in HNSCC enriched in inflammatory and profibrotic pathways. A core three-gene SIS oncogenic signature (SERPINE1, INHBA, SPP1) was identified. High SIS expression correlated with poor survival and increased CAF infiltration. Docking predicted favorable binding of ovatodiolide to SERPINE1, SPP1, and INHBA. CAF-conditioned medium enhanced the stemness and chemoresistance of HNSCC cells, promoting SIS signature and stemness markers. Ovatodiolide suppressed oncogenic properties and CAF activation, decreasing SIS and CAF markers. In a mouse model, ovatodiolide overcame cisplatin resistance by reducing the SIS signature. Conclusion: The SIS signature contributes to HNSCC progression, stemness, and drug resistance by facilitating CAF generation. Ovatodiolide disrupts this signature and inhibits CAF transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.